Using mefloquine, spironolactone, or the specific Panx1 targeting peptide PxIL2P, which is designed against the Panx1 Tyrosine 198 motif (Koval et al. 2023), Panx1 blockade reduced the duration of adrenaline and caffeine-induced atrial fibrillation in mice treated with a single dose of vascular endothelial growth factor (Mezache et al. 2023). The gene discussed is PANX1; the disease is atrial fibrillation.